What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from KEYNOTE-355 demonstrates that pembrolizumab plus chemotherapy significantly increases progression-free survival and overall survival compared to paclitaxel. The hazard ratio for overall survival was reported as 0.54, indicating a substantial clinical benefit. However, the long-term benefits remain uncertain, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for pembrolizumab combination compared to paclitaxel and docetaxel are within what NICE considers acceptable for Healthcare resources. The committee concluded that the economic model was suitable for decision-making, indicating a clear cost-effective profile.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that pembrolizumab combination improves quality of life for patients with triple-negative breast cancer, particularly for those who cannot receive atezolizumab. The committee noted that health-related quality-of-life gains were captured in the quality-adjusted life year calculations, indicating moderate improvements.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Pembrolizumab has a good safety profile, with mostly mild to moderate adverse events reported. The committee noted that serious adverse events were rare, supporting an acceptable safety rating.
Was the drug compared against what payers expect? — Comparator Selection
The company appropriately selected paclitaxel and docetaxel as comparators, which are relevant to the treatment of triple-negative breast cancer. The committee acknowledged that while atezolizumab was initially considered, it was excluded based on the specific population targeted by pembrolizumab.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, particularly focusing on those with PD-L1 expression levels that align with the marketing authorization. The committee noted the unmet need for this specific subgroup, enhancing the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab can be integrated into existing treatment pathways with minor adjustments. The committee noted that while some changes may be necessary, they are manageable within current clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of pembrolizumab are considered manageable within the Healthcare budget, especially given the potential for cost savings through effective treatment. The committee concluded that the budget impact is justifiable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust Phase III trial (KEYNOTE-355) with low bias risk. However, some methodological concerns were noted, particularly regarding the generalizability of the trial results to the broader population.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding long-term outcomes and the generalizability of trial data, the context of high unmet need and the potential benefits of pembrolizumab mitigate these concerns. The committee acknowledged the importance of addressing these uncertainties in future evaluations.
